Prosecution Insights
Last updated: October 02, 2026
Application No. 18/787,076

COMPOSITION FOR DENTIFRICE

Non-Final OA §102
Filed
Jul 29, 2024
Priority
Jul 31, 2023 — JP 2023-124379
Examiner
TRAN, SUSAN T
Art Unit
Tech Center
Assignee
GC Corporation
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
11m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
654 granted / 1041 resolved
+2.8% vs TC avg
Strong +35% interview lift
Without
With
+35.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
33 currently pending
Career history
1073
Total Applications
across all art units

Statute-Specific Performance

§101
0.9%
-39.1% vs TC avg
§103
40.9%
+0.9% vs TC avg
§102
20.9%
-19.1% vs TC avg
§112
21.8%
-18.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1041 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-3 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Yasushi et al. JP 2000154127 A. Yasushi teaches a dentifrice composition comprising sodium Fluoride 0.11%, sodium monofluorophosphate 0.39%, silica 18.0%, calcium Chloride 5.0% and water. See Example 10. Claims 1-3 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by JP2017500331 A (JP ‘331). JP ‘331 teaches a dentifrice composition comprising silica, water, calcium chloride, and sodium fluoride. See Claims. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSAN T TRAN whose telephone number is (571)272-0606. The examiner can normally be reached Monday-Friday, 8:30 am-5:30 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, ROBERT A. WAX can be reached at 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSAN T TRAN/Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Jul 29, 2024
Application Filed
Jul 29, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746266
ESSENTIAL OIL COMPOSITIONS AND APPLICATIONS UTILIZING ESSENTIAL OILS
4y 5m to grant Granted Sep 29, 2026
Patent 12746232
PATCH FOR ALLEVIATING OR TREATING SYMPTOMS OF NEURODEGENERATIVE DISEASE
3y 7m to grant Granted Sep 29, 2026
Patent 12746197
Long Acting Injectable Formulation Comprising Risperidone and Biodegradable Polymers
3y 0m to grant Granted Sep 29, 2026
Patent 12734131
LOSARTAN-CONTAINING MICRO TABLET FOR PEDIATRIC APPLICATIONS
2y 10m to grant Granted Sep 15, 2026
Patent 12721803
COMPOSITION WITH NONSILICONE ELASTOMER AND PASTY FATTY SUBSTANCE
3y 2m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
98%
With Interview (+35.1%)
3y 1m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1041 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month